

Ohio Board of Nursing www.nursing.ohio.gov

17 South High Street, Suite 400 • Columbus, Ohio 43215-7410 • (614) 466-3947

(Original New Drug Applications: FDA)			
Generic Name	Trade Name	Indication(s)	CPG Action/Date
		2013	
Alogliptin Benzoate Formulary Pg. 9	Nesina	Endocrine & Metabolic Agents: Antidiabetic Agents: Dipepetidyl Peptidase-4 Inhibitor. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	10/21/13 CTP holder may Prescribe.
Alogliptin Benzoate/ Metformin Hydrochloride Formulary Pg. 9	Kazano	Endocrine & Metabolic Agents: Antidiabetic Agents: Antidiabetic Combination Products. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both alogliptin and metformin is appropriate.	10/21/13 CTP holder may Prescribe.
Alogliptin Benzoate/ Pioglitazone Hydrochloride	Oseni	Endocrine & Metabolic Agents: Antidiabetic Agents: Antidiabetic Combination Products. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both alogliptin and pioglitazone is	10/21/13 CTP holder may Prescribe.
Formulary Pg. 9 Glycerol Phenylbutyrate Formulary Pg. 9	Ravicti	appropriate. Endocrine & Metabolic Agents: Glycerol Phenylbutyrate. Indicated for the long- term management of patients 2 years and older with urea cycle disorders who cannot be managed by dietary	10/21/13 CTP holder may Prescribe.

New Drugs October 2013

1

		protein restriction and/or amino acid supplementation alone.	
Mipomersen Sodium	Kynamro	Cardiovascular Agents: Antihyperlipidemic Agents. Indicated as an adjunct to lipid-lowering medications and diet to reduce low-density lipoprotein cholesterol, apoliprotein B, total cholesterol, and non- high-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.	10/21/13 CTP holder may Prescribe.
Bedaquiline Formulary Pg. 22	Sirturo	Anti-Infectives, Systemic: Antituberculosis Agents. Indicated as part of combination therapy in adults with pulmonary multidrug-resistant tuberculosis.	10/21/13 Physician Initiated/ Physician Consult
Meningococcal Vaccine Formulary Pg. 23	Menveo	Biologic/ Immunologic Agents: Agents for Active Immunization. Indicated for active immunization of persons 2 to 55 years of age.	10/21/13 CTP holder may Prescribe.
Pomalidomide Formulary Pg. 23	Pomalyst	Biologic/ Immunologic Agents: Immunologic Agents:Immunomodulators.Indicated for patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and bortezonib and have demonstrated disease progression on or within 60 days of completion of the last therapy.	10/21/13 Physician Initiated/ Physician Consult

June 2013			
Ospemifene Formulary Pg. 8	Osphena	Endocrine & Metabolic Agents: Sex Hormones: Selective Estrogen Receptor Modulator. Indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.	10/21/13 CTP holder may Prescribe.
Vaccinia Immune Globulin Intravenous (Human) (VIGIV)	Vaccinia Immune Globulin Intravenous	Biologic/ Immunologic Agents: Immune Globulins. Indicated for the treatment and/or modifications of the following conditions: aberrant infections induced by vaccinia virus that include its accidental implantation in eyes, mouth, or other areas where vaccinia infection would constitute a special hazard, eczema vaccinatum, progressive vaccinia, severe generalized vaccinia, and vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either activity or extensiveness of such lesions.	10/21/13 Physician Initiated/ Physician Consult
Formulary Pg. 23 Ado-Trastuzumab Emtansine	Kadcyla	Antineoplastic Agents: Antibody Drug Conjugates. Indicated as a single agent for the treatment of patients with human epidermal growth factor receptor 2 (HER2) –	10/21/13 CTP holder may NOT prescribe.

		positive, metastatic	
		breast cancer.	
Formulary Pg. 28			
r officially r g. 20	Jul	y 2013	
Canagliflozin Formulary Pg. 9	Invokana	Endocrine & Metabolic Agents: Antidiabetic Agents: Sodium-Glucose Co-Transporter 2 Inhibitors. Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.	10/21/13 CTP holder may Prescribe.
Brompheniramine Maleate	J-Tan PD	Respiratory Agents: Antihistamines. Indicated for the temporary relief of sneezing; itchy, watery eyes; itchy nose or throat; and runny nose caused by hay fever or other upper respiratory	10/21/13 CTP holder may Prescribe.
Formulary Pg. 13		allergies.	
Dexchlorpheniramine Maleate Formulary Pg. 13	Ala-Hist IR	Respiratory Agents: Antihistamines. Indicated for the temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, water eyes due to hay fever or other respiratory allergies.	10/21/13 CTP holder may Prescribe.
Chlorcyclizine Hydrochloride Formulary Pg. 13	Ahist	Respiratory Agents: Antihistamines. Indicated for the temporary relief of runny nose, sneezing, itching of the nose or throat, and itchy, water eyes due to hay fever or other respiratory allergies.	10/21/13 CTP holder may Prescribe.
Doxylamine Succinate/ Pyridoxine Hydrochloride	Diclegis	Central Nervous System Agents: Antiemetic/ Antivertigo Agents. Indicated for the treatment of nausea and	10/21/13 CTP holder may Prescribe.

T			
		vomiting of pregnancy in	
		women who do not	
		respond to conservative	
Formulary Pg. 16		management.	4.010.4.4.0
Botulism Antitoxin	Botulism Antitoxin	Biologic/ Immunologic	10/21/13
Heptavalent, (Equine)	Heptavalent	Agents: Antitoxins and	CTP holder may
		Antivenins.	Prescribe.
		Indicated for the	
		treatment of	
		symptomatic botulism	
		following documented or	
		suspected exposure to	
		Botulinum neurotoxin	
		serotypes	
		A,B,C,D,E,F,or G in	
		adults and pediatric	
Formulary Pg. 23	T <i>C</i> - I -	patients.	40/04/40
Dimethyl Fumarate	Tecfidera	Biologic / Immunologic	10/21/13
		Agents:	Physician Initiated/
		Immunomodulators.	Physician Consult
		Indicated for the	
		treatment of patients	
		with relapsing forms of multiple sclerosis.	
Formulary Pg. 23		multiple scierosis.	
Torritulary Fg. 25	Δυσυ	st 2013	
Prothrombin Complex	Kcentra	Hematological Agents:	10/21/13
Concentrate (Human)	Roonad	Hemostatics.	Physician Initiated/
		Indicated for the urgent	Physician Consult
		reversal of acquired	y
		coagulation factor	
		deficiency induced by	
		vitamin K antagonist	
		(e.g. warfarin) therapy in	
		adult patients with acute	
Formulary Pg. 7		major bleeding.	
Levonorgestrel	Skyla	Endocrine & Metabolic	10/21/13
_		Agents: Sex Hormones:	CTP holder may
		Contraceptive	Prescribe.
		Hormones.	
		Indicated for the	
		prevention of pregnancy	
		for up to 3 years.	
Formulary Pg. 8			
Budesonide Oral	Uceris	Endocrine & Metabolic	10/21/13
		Agents: Adrenocortical	CTP holder may
		Steriods:	Prescribe.
		Glucocorticoids.	
		Indicated for the	
		induction of remission in	

		notionto with active will a	1
		patients with active mild to moderate ulcerative	
		colitis.	
Formulary Pg. 9			
Ezetimibe/	Liptruzet	Cardiovascular Agents:	10/21/13
Atorvastatin		Antihyperlipidemic	CTP holder may
		Agents: Combination	Prescribe.
		Agents.	
		Indicated as an adjunct	
		to diet for the reduction	
		of elevated total	
		cholesterol, and low- density lipoprotein	
		cholesterol in patients	
		with other lipid- lowering	
		treatments or is such	
		treatments are	
Formulary Pg. 11		unavailable.	
Ciclesonide	Alvesco	Respiratory Agents:	10/21/13
		Respiratory Inhalant	CTP holder may
		Products. Indicated for the	Prescribe.
		maintenance treatment	
		of asthma as	
		prophylactic therapy in	
		adult and adolescent	
		patients 12 years of age	
Formulary Pg. 13		and older.	
Aripiprazole	Abilify Maintena	Central Nervous System	10/21/13
		Agents: Antipsychotic	CTP holder may prescribe for Psych
		Agents: Quinolinone Derivatives.	CTP holder.
		Indicated for the	Physician Initiated/
		treatment of	Physician Consult
Formulary Pg. 17		schizophrenia.	for CTP holders
			other than psych.
Immune Globulin	Bivigam	Biologic/ Immunologic	10/21/13
(Human) Intravenous		Agents: Immune	Physician Initiated/
		Globulins.	Physician Consult
		Indicated for the treatment of patients	
		with primary humoral	
Formulary Pg. 23		immunodeficiency.	
, , , , , , , , , , , , , , , , , , ,			
Radium RA 223	Xofigo	Antineoplastic Agents:	10/21/13
Dichloride	-	Radiopharmaceuticals.	CTP holder may
		Indicated for the	NOT prescribe.
		treatment of patients	
		with castration-resistant	
		prostate cancer,	

		symptomatic bone	
		metastases, and no known visceral	
		metastatic disease.	
Formulary Da 27		metastatic disease.	
Formulary Pg. 27	Sonto	mber 2013	
Fluticasone Furoate/	Breo Ellipta		10/21/13
Vilanterol		Respiratory Agents: Respiratory Inhalant	CTP holder may
Vilanteroi		Combinations.	Prescribe.
		Indicated for the	Flescibe.
		maintenance treatment	
		of airflow obstruction in	
		patients with chronic	
		obstructive pulmonary	
		disease (COPD),	
		including chronic	
		bronchitis and/or	
		emphysema. It is also	
		indicated to reduce	
		exacerbations of COPD	
		in patients with a history	
Formulary Pg. 13		of exacerbations.	
Lorcaserin	Belviq	Central Nervous System	10/21/13
Hydrochloride	- 1	Agents: Anorexiants.	CTP holder may
		Indicated as an adjunct	NOT prescribe.
		to a reduced-calorie diet	
		and increased physical	
		activity for chronic	
		weight management in	
		adult patients with an	
		initial body bass index of	
		30 or greater or 27 or	
		greater in the presence	
		of at least 1 weight	
		related comorbid	
Formulary Pg. 15	T C ·	condition.	40/04/40
Dabrafenib	Tafinlar	Antineoplastic Agents:	10/21/13
		Kinase Inhibitors.	CTP holder may
		Indicated for the treatment of	NOT prescribe.
		unresectable or	
		metastatic melanoma in	
		patients with a BRAF	
Formulary Pg. 28		V600E mutation.	
Trametinib	Mekinist	Antineoplastic Agents:	10/21/13
	WORLDO	Kinase Inhibitors.	CTP holder may
		Indicated for the	NOT prescribe.
		treatment of	
		unresectable metastatic	
		melanoma in patients	

	with a BRAF V600E or BRAF V600K mutation as detected by a Food
	and Drug Administration
Formulary Pg. 28	(FDA) approved test.

New Drugs Indications/ Warnings October 2013 (New Drug Indications/ Black Box Warnings: FDA

· · · · · · · · · · · · · · · · · · ·		k Box Warnings: FDA	CDC Astism/Data	
Generic Name	Trade Name	Indication(s)	CPG Action/Date	
May 2013				
Telaprevir	Incivek	Anti-Infectives,	Current: Physician	
		Systemic: Antiviral	Initiated/ Physician	
		Agents.	Consult	
		New black box warning		
		for fatal and nonfatal	10/21/13	
		serious skin reactions,	No change	
		including Stevens-		
		Johnson syndrome, drug		
		reaction with		
		eosinophilia and		
		systemic symptoms, and		
		toxic epidermal		
		necrolysis, have been		
		reported in patients		
		treated with telaprevir		
Formulary Pg. 22		combination treatment.	Ourset Dhusisian	
Anakinra	Kineret	Biologic/ Immunologic	Current: Physician	
		Agents:	Initiated/ Physician	
		Immunomodulators.	Consult.	
		New indication for the	10/01/10	
		treatment of neonatal-	10/21/13 No change	
Formulary Da 22		onset multisystem inflammatory diseases.	No change	
Formulary Pg. 23	lur	10 2013		
2020	Jui			
none		ly 2013		
	Jui			
none				
		ust 2013		
Regorafenib	Stivarga	Antineoplastic Agents:	Current: CTP holder	
		Kinase Inhibitors.	may NOT prescribe.	
		New indication for the	40/04/40	
		treatment of patients	10/21/13	
		with locally advanced,	No change	
		unresectable or		
		metastatic GI stromal		
		tumor who have been		
Formulary Da. 29		previously treated with		
Formulary Pg. 28	0	imatinib and sunitinib.		
<u>Everalizava</u>	-	mber 2013	Cumanti Dhusisian	
Everolimus	Zotress	Antineoplastic Agents:	Current: Physician	

	Kinase Inhibitors.	Initiated/ Physician
	New indication for the	Consult for
	prophylaxis of allograft	prophylaxis of organ
	rejection in adult patients	rejection in kidney
	receiving a liver	transplants.
	transplant in	
	combination with	10/21/13
	tacrolimus and	No change
Formulary Pg. 28	corticosteroids.	

Formulary Revision Request October 2013 (Original New Drug Applications: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action/Date	
Formulary Review Revision Request from Susan E. Busch, CNP				
Cinacalcet	Sensipar	Endocrine & Metabolic Agents: Calcitonin- Salmon. Indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma and primary hyperparathyroidism, and for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.	Current: Physician Initiated/ Physician Consult 10/21/13 CTP holder may prescribe.	
Formulary Pg. 10		Requesting: CTP holder may prescribe.		
Formulary Re	view Revision Request fr	om Carol Cairns, MSN, AC	NP-BC, CNP	
Ketamine	Ketalar	Central Nervous System Agents: General Anesthetics. Indicated as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation and for the induction of anesthesia prior to the administration of other general anesthetic	Current: CTP holder may NOT prescribe. 10/21/13 CTP holder may prescribe in institutional setting per institutional standards for urgent and emergent respiratory care.	

		agents.	
		0	
		Requesting: Per	
		institution protocol	
Formulary Pg. 18		·····	
Etomidate	Amidate	Central Nervous System Agents: General Anesthetics. Indicated for the induction of general anesthesia and the supplementation of subpotent anesthetic agents during maintenance of general anesthesia for short operative procedures.	Current: CTP holder may NOT prescribe. 10/21/13 CTP holder may prescribe in institutional setting per institutional standards for urgent and emergent respiratory care.
Ferraulari Dr. 40		Requesting: Per	
Formulary Pg. 18 Propofol	Diprivan	institution protocol Central Nervous System	Current: CTP holder
	Diprivari	Agents: General Anesthetics. Indicated for the induction or maintenance of anesthesia as part of a balanced anesthetic technique for inpatient and outpatient surgery, for maintenance of anesthesia, to initiate and maintain MAC sedation during diagnostic procedures, for MAC sedation in conjunction with local/regional anesthesia in patients undergoing surgical procedures, and for continuous sedation and control of stress responses in intubated or respiratory-controlled adult patients in ICUs.	10/21/13 CTP holder may prescribe in institutional setting per institutional standards for urgent and emergent respiratory care.
Formulary Pg. 18		Requesting: Per Institution Protocol	

Rocuronium Bromide	Zemuron	Central Nervous System Agents: Muscle Relaxants- Adjuncts to Anesthesia. Indicated as an adjunct to general anesthesia for inpatients and outpatients to facilitate rapid sequence and routine tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.	Current: CTP holder may NOT prescribe. 10/21/13 CTP holder may prescribe in institutional setting per institutional standards for urgent and emergent respiratory care.
		Requesting: Per	
Formulary Pg. 19		Institution Protocol.	
Succinylcholine Chloride	Anectine, Quelicin	Central Nervous System Agents: Muscle Relaxants- Adjuncts to Anesthesia. Indicated as an adjunct to general anesthesia to facilitate endotracheal intubation, and to induce skeletal muscle relaxation during surgery or mechanical ventilation.	Current: CTP holder may NOT prescribe. 10/21/13 CTP holder may prescribe in institutional setting per institutional standards for urgent and emergent respiratory care.
Formulary Pg. 19		Requesting: Per Institution Protocol.	

Formulary Review Revision Request from Cindy Edwards-Tuttle, FNP-BC

Fluorouracil	Carac, Efudex,	Dermatological Agents:	Current: CTP holder
	Fluoroplex	Pyrimidine Antagonist,	may prescribe for
		Topical.	CTP holders with
		Indicated for the topical	SCA with physician
		treatment of multiple	specializing in
		actinic or solar keratosis	Derm. or Physician
		and for the treatment of	Initiated/ Physician
		superficial basal cell	Consult.
		carcinomas when	
		conventional methods	10/21/13
		are impractical, such as	CTP holder may
		with multiple lesion sites.	prescribe.

		1		
Formulary Pg. 24 Methotrexate	Rhematrex Dose Pack, Trexall	Requesting: CTP holder may prescribe. Biologic/ Immunologic Agents: Antirheumatic Agents. Indicated for the treatment of severe, active, classical or definite adult rheumatoid arthritis in adults who	Current: Physician Initiated/ Physician Consult 10/21/13 Discussion tabled until January 13, 2014 meeting.	
		have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first line therapy including full dose NSAIDS and for the management of children with active polyarticular-course JRA who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full- dose NSAIDS		
Methotrexate		Dermatologic Agents: Anti-Psoriatic Agents. Indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis, which is not adequately responsive to other therapy.	10/21/13 Discussion tabled until January 13, 2014 meeting.	
Formulary Pg. 24		Requesting: CTP holder May prescribe.		
Formulary Review Revision Request from David Holloway, MSN, ACNP, CCRN, CPRN				
Propofol	Diprivan	Central Nervous System Agents: General Anesthetics. Indicated for the	Current: CTP holder may NOT prescribe.	

Formulary Pg. 18		maintenance of anesthesia as part of a balanced anesthetic technique for inpatient and outpatient surgery, for maintenance of anesthesia, to initiate and maintain MAC sedation during diagnostic procedures, for MAC sedation in conjunction with local/regional anesthesia in patients undergoing surgical procedures, and for continuous sedation and control of stress responses in intubated or respiratory-controlled adult patients in ICUs. Requesting: Only Acute Care/ Critical Care NP may prescribe in critical care setting for sedation of patients who have a secure artificial airway and receiving mechanical ventilation. CTP holder may not prescribe for the purposes of conscious sedation during procedures or the induction of general anesthesia prior to the establishment of a secure artificial airway.	10/21/13 CTP holder may prescribe in institutional setting per institutional standards for urgent and emergent respiratory care.
Formulary	Review Revision Rev	quest from Louise A. Smith,	RN. CNP
		· · · · · · · · · · · · · · · · · · ·	
Atorvastatin	Lipitor	Cardiovascular Agents: Antihyperlipidemic Agents: HMG-CoA Inhibitors.	Current: CTP holder may prescribe or Physician Initiated/ Physician Consult

Indicated to reduce the

risk of myocardial infarction, for treatment

dysbetalipoproteinemia, as an adjunct to diet to

of

for pediatric dosing.

CTP holder may

10/21/13

prescribe.

Formulary Pg. 11		reduce elevated total cholesterol, to reduce total cholesterol in boys and premenarchal girls 10-17 years of age, to reduce total cholesterol in patients with homozygous FH, and for the treatment of patients with elevated serum triglyceride levels. Requesting: CTP holder may prescribe.	
Formulary Re	view Revision Request	from Melissa A. Telenko, N	ISN, FNP-BC
Methoxsalen Oral	Oxsoralen Ultra	Dermatological Agents:PhotochemotherapyAgents.Indicated for thesymptomatic control ofsevere, recalcitrant,disabling psoriasis notadequately responsiveto other forms of therapyand when the diagnosishas been supported bybiopsy.Indicated as a topicalrepigmenting agent invitiligo, used inconjunction withcontrolled doses ofultraviolet A or sunlight.Requesting: PhysicianInitiated/ PhysicianConsult with a	Current: CTP holder may NOT prescribe. 10/21/13 Physician Initiated/ Physician Consult for CTP holder with SCA with a physician specializing in dermatology. 10/21/13 Physician Initiated/ Physician Consult for CTP holder with SCA with a physician specializing in dermatology.
Formulary Pg. 25		dermatologist	
-	-	son Wannemacher, MSN,	
Propofol	Diprivan	Central Nervous System Agents: General Anesthetics. Indicated for the maintenance of anesthesia as part of a balanced anesthetic technique for inpatient	Current: CTP holder may NOT prescribe. 10/21/13 CTP holder may prescribe in institutional setting per institutional

Formulary Pg. 18		and outpatient surgery, for maintenance of anesthesia, to initiate and maintain MAC sedation during diagnostic procedures, for MAC sedation in conjunction with local/regional anesthesia in patients undergoing surgical procedures, and for continuous sedation and control of stress responses in intubated or respiratory-controlled adult patients in ICUs. Requesting: Only Acute Care/ Critical Care NP may prescribe in critical care setting for sedation of patients who have a secure artificial airway and receiving mechanical ventilation. CTP holder may not prescribe for the purposes of conscious sedation during procedures or the induction of general anesthesia prior to the establishment of a secure artificial airway. Requesting: CTP holder may prescribe for ACNP in critical care-like setting.	standards for urgent and emergent respiratory care.
Formu	lary Review Revision R	equest from Susan Yeager,	, CNP
Nimodipine	Nimodipine	Cardiovascular Agents:	Current: Physician
		Calcium Channel Blocking Agents	Initiated/ Physician

Nimodipine	Nimodipine	Cardiovascular Agents:	Current: Physician
		Calcium Channel	Initiated/ Physician
		Blocking Agents.	Consult
		Indicated for the	
		improvement of	10/21/13
		neurological outcome by	CTP holder may
		reducing the incidence	prescribe.
		and severity or ischemic	
		deficits in patients with	
		SAH from ruptured	

Formulary Pg. 11	intracranial berry aneurysms regardless of their postictus neurological condition.
	Requesting: CTP holder may prescribe.

Review of Prescribing Designations PI/PC and CTP Holder May <u>NOT</u> Prescribe

Cardiovascular Agents (October 2013)

Drug Category/Drug Name	Indications(s)	Current Prescribing Designation	CPG Action/Date		
	Calcium Channel Blocking Agents				
Nimodipine (Nimodipine, Nimotop)	Calcium Channel Blocking Agents. Indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage.	Physician Initiated/ Physician Consult	10/21/13 CTP holder may prescribe.		
Formulary Pg. 11	Monodi				
	Vasodi	lators			
Endothelin Receptor Antagonist	Vasodilators: Endothelin Receptor Antagonist.	Physician Initiated/ Physician Consult	10/21/13 No change		
Formulary Pg. 11					
Peripheral Vasodilators			10/21/13 Physician Initiated/ Physician Consult		
Epoprostenol Sodium Injection (Flolan)	Vasodilators: Peripheral Vasodilators. Indicated for the long-	Physician Initiated/ Physician Consult for CTP holder within			

		1	
Formulary Pg. 11	term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.	specialty clinic.	10/21/13 Physician Initiated/ Physician Consult
Treprostinil Sodium (Remodulin)	Vasodilators: Peripheral Vasodilators: Peripheral Vasodilators. Indicated for the treatment of pulmonary arterial hypertension in patients with New York Heart Association (NYAH) class II to IV symptoms to diminish symptoms associated with exercise, and to diminish the rate of clinical deterioration in patients requiring transition from epoprostenol.	Physician Initiated/ Physician Consult for CTP holder within specialty clinic.	10/21/13 Physician Initiated/ Physician Consult
Treprostinil Inhalation	Indicated to increase walk distance in patients with World Health Organization group I pulmonary arterial hypertension and New York Heart Association class II symptoms.	Physician Initiated/ Physician Consult.	10/21/13 No change
Formulary Pg. 11	Veeediletere	Dhusisian Initiated/	10/01/10
Vasodilator Combinations	Vasodilators: Vasodilator Combinations.	Physician Initiated/ Physician Consult	10/21/13 CTP holder may prescribe.
Isosorbide Dinitrate/ Hydralazine Hydrochloride (BiDil)	Indicated for the treatment of heart failure as an adjunct to standard therapy in self- identified black patients to improve survival, to prolong time to hospitalization for heart		

Formulary Pg. 11	failure, and to improve patient-reported functional status.		
	Agents for Pheo	ochromocytoma	
Agents for Pheochromocytoma	Agents for Pheochromocytoma	CTP holder May NOT prescribe.	10/21/13 No Change
Formulary Pg. 11			
	Antihyperlipio	demic Agents	
HMG-CoA Reductase Inhibitors	Antihyperlipidemic Agents: HMG-CoA Reductase Inhibitors. Indicated for primary prevention of cardiovascular disease in patients with multiple risk factors, reducing angina risk, reducing MI risk, reducing stroke risk, reducing risk for revascularization procedures, reduce risk of CV mortality, slow progression of coronary atherosclerosis, reduce risk of total mortality by reducing coronary death, and	Physician Initiated/ Physician Consult for pediatric dosing.	10/21/13 CTP holder may prescribe.
Formulary Pg. 11	hypercholesterolemia.		
	Cardioplegi	c Solutions	
Cardioplegic Solution (Plegisol)	Cardioplegic Solutions. Indicated for inducing cardiac arrest during	CTP holder May NOT prescribe.	10/21/13 No change
Formulary Pg. 12	open-heart surgery.		
	Agents for Patent	Ductus Arteriosus	
Alprostadil (Prostin VR Pediatric)	Agents for Patent Ductus Arteriosus. Indicated for palliative, not definitive, therapy	Physician Initiated/ Physician Consult	10/21/13 No change

Formulary Pg. 12	to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival.		40/04/40
Ibuprofen Lysine (NeoProfen)	Agents for Patent Ductus Arteriosus. Indicated to close a clinically significant PDA in premature infants who are no more than 32 weeks gestational age when usual medical management is ineffective.	Neonatal NP CTP holder only may prescribe. Physician Initiated/ Physician Consult all other CTP holders.	10/21/13 No change
Formulary Pg. 12			
Indomethacin (Indocin I.V.)	Agents for Patent Ductus Arteriosus. Indicated for closure of hemodynamically significant PDA in premature infants if, after 48 hours, usual medical management is ineffective.	Neonatal NP CTP holder only may prescribe. Physician Initiated/ Physician Consult all other CTP holders.	10/21/13 No change
Formulary Pg. 12	Sclerosin	g Agents	
Sclerosing Agents	Sclerosing Agents. Indicated for treatment of small, uncomplicated varicose veins of the lower extremities.	CTP holder May NOT prescribe.	10/21/13 CTP holder may prescribe.
Polidocanol (Asclera) Formulary Pg. 12	Indicated to treat uncomplicated spider veins and uncomplicated reticular veins in the lower extremity.		